New drug may ease ENT symptoms in rare autoimmune disease

NCT ID NCT07176546

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 24 times

Summary

This study tests whether adding TAVNEOS to standard treatment helps control ear, nose, and throat symptoms in people with granulomatosis with polyangiitis (GPA), a rare autoimmune disease. About 30 adults with active ENT disease will receive either TAVNEOS or a placebo for 52 weeks. The goal is to see if more people achieve symptom remission without needing steroids.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRANULOMATOSIS WITH POLYANGIITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hackensack Meridian School of Medicine - Advanced Lung and Airway Center

    Edison, New Jersey, 08820, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital for Special Surgery

    New York, New York, 10021, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.